Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis

Gregory Y H Lip, Piotr Ponikowski, Felicita Andreotti, Stefan D. Anker, Gerasimos Filippatos, Shunichi Homma, Joao Morais, Patrick Pullicino, Lars H. Rasmussen, Francisco Marin, Deirdre A. Lane

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Chronic heart failure (HF) with either reduced or preserved left ventricular (LV) ejection fraction is common and remains an extremely serious disorder with a high mortality and morbidity. Many complications related to heart failure can be related to thrombosis. Epidemiological and pathophysiological data also link HF to an increased risk of thrombosis, leading to the clinical consequences of sudden death, stroke, systemic thromboembolism and/or venous thromboembolism. This executive summary of a joint consensus document of the Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis reviews the published evidence, summarises 'best practice', and puts forward consensus statements that may help to define evidence gaps and assist management decisions in everyday clinical practice. In HF patients with atrial fibrillation, oral anticoagulation is clearly recommended, and the CHA2DS2-VASc and HAS-BLED scores should be used to determine the likely risk-benefit ratio (thromboembolism prevention versus risk of bleeding) of oral anticoagulation. In HF patients with reduced LV ejection fraction who are in sinus rhythm there is no evidence of an overall benefit of vitamin K antagonists (e.g. warfarin) on mortality, with risk of major bleeding. Whilst there is the potential for a reduction in ischaemic stroke, there is currently no compelling reason to routinely use warfarin for these patients. Risk factors associated with increased risk of thromboembolic events should be identified and decisions regarding use of anticoagu-lation individualised. Patient values and preferences are important determinants when balancing the risk of thromboembolism against bleeding risk. Novel oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials.

Original languageEnglish
Pages (from-to)1009-1022
Number of pages14
JournalThrombosis and Haemostasis
Volume108
Issue number6
DOIs
Publication statusPublished - 2012

Fingerprint

Thromboembolism
Cardiology
Thrombosis
Heart Failure
Joints
Warfarin
Hemorrhage
Stroke Volume
Therapeutics
Stroke
Vitamin K
Mortality
Patient Preference
Venous Thromboembolism
Sudden Death
Practice Guidelines
Anticoagulants
Atrial Fibrillation
Odds Ratio
Clinical Trials

Keywords

  • Antithrombotic therapy
  • Aspirin
  • Heart failure
  • Sinus rhythm
  • Thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm : An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis. / Lip, Gregory Y H; Ponikowski, Piotr; Andreotti, Felicita; Anker, Stefan D.; Filippatos, Gerasimos; Homma, Shunichi; Morais, Joao; Pullicino, Patrick; Rasmussen, Lars H.; Marin, Francisco; Lane, Deirdre A.

In: Thrombosis and Haemostasis, Vol. 108, No. 6, 2012, p. 1009-1022.

Research output: Contribution to journalArticle

Lip, Gregory Y H ; Ponikowski, Piotr ; Andreotti, Felicita ; Anker, Stefan D. ; Filippatos, Gerasimos ; Homma, Shunichi ; Morais, Joao ; Pullicino, Patrick ; Rasmussen, Lars H. ; Marin, Francisco ; Lane, Deirdre A. / Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm : An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis. In: Thrombosis and Haemostasis. 2012 ; Vol. 108, No. 6. pp. 1009-1022.
@article{73b55441669249098e15ed0d1f2bf372,
title = "Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis",
abstract = "Chronic heart failure (HF) with either reduced or preserved left ventricular (LV) ejection fraction is common and remains an extremely serious disorder with a high mortality and morbidity. Many complications related to heart failure can be related to thrombosis. Epidemiological and pathophysiological data also link HF to an increased risk of thrombosis, leading to the clinical consequences of sudden death, stroke, systemic thromboembolism and/or venous thromboembolism. This executive summary of a joint consensus document of the Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis reviews the published evidence, summarises 'best practice', and puts forward consensus statements that may help to define evidence gaps and assist management decisions in everyday clinical practice. In HF patients with atrial fibrillation, oral anticoagulation is clearly recommended, and the CHA2DS2-VASc and HAS-BLED scores should be used to determine the likely risk-benefit ratio (thromboembolism prevention versus risk of bleeding) of oral anticoagulation. In HF patients with reduced LV ejection fraction who are in sinus rhythm there is no evidence of an overall benefit of vitamin K antagonists (e.g. warfarin) on mortality, with risk of major bleeding. Whilst there is the potential for a reduction in ischaemic stroke, there is currently no compelling reason to routinely use warfarin for these patients. Risk factors associated with increased risk of thromboembolic events should be identified and decisions regarding use of anticoagu-lation individualised. Patient values and preferences are important determinants when balancing the risk of thromboembolism against bleeding risk. Novel oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials.",
keywords = "Antithrombotic therapy, Aspirin, Heart failure, Sinus rhythm, Thromboembolism, Warfarin",
author = "Lip, {Gregory Y H} and Piotr Ponikowski and Felicita Andreotti and Anker, {Stefan D.} and Gerasimos Filippatos and Shunichi Homma and Joao Morais and Patrick Pullicino and Rasmussen, {Lars H.} and Francisco Marin and Lane, {Deirdre A.}",
year = "2012",
doi = "10.1160/TH12-08-0578",
language = "English",
volume = "108",
pages = "1009--1022",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm

T2 - An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis

AU - Lip, Gregory Y H

AU - Ponikowski, Piotr

AU - Andreotti, Felicita

AU - Anker, Stefan D.

AU - Filippatos, Gerasimos

AU - Homma, Shunichi

AU - Morais, Joao

AU - Pullicino, Patrick

AU - Rasmussen, Lars H.

AU - Marin, Francisco

AU - Lane, Deirdre A.

PY - 2012

Y1 - 2012

N2 - Chronic heart failure (HF) with either reduced or preserved left ventricular (LV) ejection fraction is common and remains an extremely serious disorder with a high mortality and morbidity. Many complications related to heart failure can be related to thrombosis. Epidemiological and pathophysiological data also link HF to an increased risk of thrombosis, leading to the clinical consequences of sudden death, stroke, systemic thromboembolism and/or venous thromboembolism. This executive summary of a joint consensus document of the Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis reviews the published evidence, summarises 'best practice', and puts forward consensus statements that may help to define evidence gaps and assist management decisions in everyday clinical practice. In HF patients with atrial fibrillation, oral anticoagulation is clearly recommended, and the CHA2DS2-VASc and HAS-BLED scores should be used to determine the likely risk-benefit ratio (thromboembolism prevention versus risk of bleeding) of oral anticoagulation. In HF patients with reduced LV ejection fraction who are in sinus rhythm there is no evidence of an overall benefit of vitamin K antagonists (e.g. warfarin) on mortality, with risk of major bleeding. Whilst there is the potential for a reduction in ischaemic stroke, there is currently no compelling reason to routinely use warfarin for these patients. Risk factors associated with increased risk of thromboembolic events should be identified and decisions regarding use of anticoagu-lation individualised. Patient values and preferences are important determinants when balancing the risk of thromboembolism against bleeding risk. Novel oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials.

AB - Chronic heart failure (HF) with either reduced or preserved left ventricular (LV) ejection fraction is common and remains an extremely serious disorder with a high mortality and morbidity. Many complications related to heart failure can be related to thrombosis. Epidemiological and pathophysiological data also link HF to an increased risk of thrombosis, leading to the clinical consequences of sudden death, stroke, systemic thromboembolism and/or venous thromboembolism. This executive summary of a joint consensus document of the Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis reviews the published evidence, summarises 'best practice', and puts forward consensus statements that may help to define evidence gaps and assist management decisions in everyday clinical practice. In HF patients with atrial fibrillation, oral anticoagulation is clearly recommended, and the CHA2DS2-VASc and HAS-BLED scores should be used to determine the likely risk-benefit ratio (thromboembolism prevention versus risk of bleeding) of oral anticoagulation. In HF patients with reduced LV ejection fraction who are in sinus rhythm there is no evidence of an overall benefit of vitamin K antagonists (e.g. warfarin) on mortality, with risk of major bleeding. Whilst there is the potential for a reduction in ischaemic stroke, there is currently no compelling reason to routinely use warfarin for these patients. Risk factors associated with increased risk of thromboembolic events should be identified and decisions regarding use of anticoagu-lation individualised. Patient values and preferences are important determinants when balancing the risk of thromboembolism against bleeding risk. Novel oral anticoagulants that offer a different risk-benefit profile compared with warfarin may appear as an attractive therapeutic option, but this would need to be confirmed in clinical trials.

KW - Antithrombotic therapy

KW - Aspirin

KW - Heart failure

KW - Sinus rhythm

KW - Thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84870937675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870937675&partnerID=8YFLogxK

U2 - 10.1160/TH12-08-0578

DO - 10.1160/TH12-08-0578

M3 - Article

C2 - 23093044

AN - SCOPUS:84870937675

VL - 108

SP - 1009

EP - 1022

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -